This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial | MicrobiomeTrials
← Back to trials NCT07426705
Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial Recruiting PHASE4 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-02-15Est. Completion: 2027-07-15
Enrollment target: 100 participantsOther microbiome trials you might be interested in Functional Dyspepsia Small Intestinal Bacterial Overgrowth
The purpose of this study is to investigate the prevalence of small intestinal bacterial overgrowth (SIBO) in patients w…
Indianapolis, United States Completed Dec 2026
Eosinophilic Esophagitis Gastroesophageal Reflux Disease (GERD) Gastroparesis Functional Vomiting Irritable Bowel Syndrome (IBS) Constipation Chronic Intestinal Pseudo-obstruction Fecal Incontinence Small Intestinal Bacterial Overgrowth
Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to …
Indianapolis, United States Est. completion Nov 2026
Autoimmune Hepatitis
Pediatric autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH) and overlap syndromes like sclerosing …
New Delhi, India Est. completion Apr 30, 2028